ACTU · Actuate Therapeutics, Inc.
$1.27
+0.04 (+3.25%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$30.50M
Shares
24.01M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.27
Open$1.22
Day$1.18–1.34
52W close$0.97–8.72
Avg vol 30d379K
Short int450K · 1.9% float · 2.9d
Short vol34%
DataAug 2024–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−10%
below
RSI (14)
54
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−66%
trailing
YTD return
−79%
this year
Relative strength
−78%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.87% of float · ▼ -40.4% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 2-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
EPS growth
+67%
Y/Y
Balance sheet
$13.2M
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
12.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.87% of float · ▼ -40.4% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 4%
Range high $9
vs 200-day avg -64%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACTU
this stock
Actuate Therapeutics, Inc.
|
$30.50M | -79.2% | — | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACTU | +25.7% | +7.6% | -66.1% | +14.4% | -79.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +27.1% | +4.0% | -77.7% | +11.9% | -91.5% |
Key facts
CIK
1652935
CUSIP
005083100
13F (30d)
53 filings
53 filers
Visit website
Investor relations